...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antimicrobial agents and chemotherapy. >In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.
【24h】

In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

机译：新的利福霉素衍生物KRM-1648和KRM-1657的体外抗幽门螺杆菌活性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated for their in vitro antimicrobial activities against 44 strains of Helicobacter pylori. Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of isolates are inhibited for these drugs were lower (0.002 and 0.008 microgram/ml, respectively) than those of amoxicillin and rifampin for H. pylori. Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be useful for the eradication of H. pylori infections.
机译：评估了新的利福霉素衍生物KRM-1657和KRM-1648对44株幽门螺杆菌的体外抗菌活性。尽管这些药物对其他革兰氏阴性细菌的活性不是很强，但抑制90％分离物的MIC低于阿莫西林和利福平对幽门螺杆菌的MIC（分别为0.002和0.008微克/ ml）。时间杀灭研究表明，这些药剂的杀菌活性是由于细胞裂解所致。此处显示的结果表明，这些新的利福霉素衍生物可能对根除幽门螺杆菌感染有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号